Entera Bio Ltd. 8-K

What Happened Entera Bio Ltd. (Israel) filed an 8-K dated July 16, 2026, disclosing shareholder approvals at its Annual Meeting. Shareholders approved an amendment to the company’s Articles of Association to increase authorized Ordinary Shares from 140,010,000 to 350,000,000. They also approved a one-time increase of 2,500,000 Ordinary Shares to the company’s 2018 Equity Incentive Plan. The filed exhibits include the amended Articles (Exhibit 3.1) and the plan amendment (Exhibit 10.1).

Key Details

• Authorized Ordinary Shares increased from 140,010,000 to 350,000,000 (Articles Amendment effective upon shareholder approval).
• 2018 Equity Incentive Plan increased by a one-time grant of 2,500,000 Ordinary Shares.
• Company: Entera Bio Ltd., ordinary shares par value NIS 0.0000769; filing date July 16, 2026.
• Exhibits: Amended and Restated Articles of Association (Exhibit 3.1) and Amendment to 2018 Equity Incentive Plan (Exhibit 10.1) are filed with the 8-K.

Why It Matters These approvals give Entera Bio greater flexibility to issue additional shares for corporate purposes such as financing, acquisitions, or equity compensation. The increase to the equity incentive plan expands the pool available for employee, director, or consultant awards. If and when new shares are issued under the expanded authorization or plan, existing shareholders could experience dilution; investors should review the filed exhibits and the company’s future disclosures for details on any planned issuances.